Edition:
United States

Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Capital Market

9.16USD
24 May 2017
Change (% chg)

-- (--)
Prev Close
$9.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
177,094
52-wk High
$16.29
52-wk Low
$6.97

Latest Key Developments (Source: Significant Developments)

Advaxis Inc- European Medicines Agency issued an advanced therapy medicinal product certificate
Thursday, 23 Mar 2017 08:00am EDT 

Advaxis Inc :Advaxis Inc - European Medicines Agency issued an advanced therapy medicinal product certificate for manufacturing quality and non-clinical data.  Full Article

Advaxis says 38 pct of patients with heavily pretreated prmcc were alive 12 months following treatment with axalimogene filolisbac
Wednesday, 15 Mar 2017 07:00am EDT 

Advaxis Inc : Advaxis presents oral late-breaking data on phase 2 gog-0265 study of axalimogene filolisbac . Advaxis - final efficacy results of gog-0265 demonstrated 38% of patients with heavily pretreated prmcc were alive 12 months following treatment with axalimogene filolisbac .Advaxis inc - safety profile was consistent with previous clinical experience.  Full Article

Advaxis announces FDA acceptance of IND for groundbreaking personalized neoepitope immunotherapy, ADXS-NEO
Monday, 6 Mar 2017 06:00am EST 

Advaxis Inc : Advaxis announces FDA acceptance of IND for groundbreaking personalized neoepitope immunotherapy, ADXS-NEO .Plans to initiate a phase 1 trial evaluating ADXS-NEO in multiple tumor types later this year.  Full Article

Advaxis and Sellas announce licensing agreement for development of WT1 antigen-targeting immunotherapy
Monday, 27 Feb 2017 08:00am EST 

Advaxis Inc : Advaxis and Sellas announce licensing agreement for development of WT1 antigen-targeting immunotherapy . Advaxis Inc- Advaxis will receive future payments of up to $358 million from Sellas if certain development, regulatory, and commercial milestones are met . Advaxis Inc says advaxis will receive future payments of up to $358 million from Sellas if certain development, regulatory . Under terms of collaboration, Advaxis will conduct all pre-clinical activities required for an Ind Filin . Advaxis Inc says Sellas will be responsible for all clinical development and commercial activities .Advaxis -after regulatory approval of product Sellas to pay Advaxis single-digit to low double-digit royalties based on worldwide net sales upon commercialization.  Full Article

Advaxis files for common stock offering of up to $250 mln
Friday, 10 Feb 2017 04:58pm EST 

Advaxis Inc :Advaxis Inc files for common stock offering of up to $250 million - SEC filing.  Full Article

Amgen reports 8.9 pct passive stake in Advaxis as of Aug 1
Tuesday, 2 Aug 2016 09:06am EDT 

Amgen Inc Reports 8.9 Pct Passive Stake In Advaxis Inc As Of August 1 :Sec filing.  Full Article

Advaxis files for common stock offering
Tuesday, 2 Aug 2016 08:49am EDT 

Advaxis Inc :Files for common stock offering of up to 3.05 million shares - SEC filing.  Full Article

Advaxis Inc says FDA grants advaxis fast track designation for ADXS-HER2
Thursday, 28 Apr 2016 07:05am EDT 

Advaxis Inc:Says FDA has granted fast track designation for company's immunotherapy product candidate ADXS-HER2 for patients with newly-diagnosed, non-metastatic, surgically-resectable osteosarcoma.  Full Article

Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma
Tuesday, 1 Dec 2015 09:05am EST 

Advaxis, Inc:Says that the European Medicines Agency (EMA) granted Orphan Drug Designation for ADXS-HER2 for the treatment of osteosarcoma.  Full Article

Advaxis reports clinical hold of investigational agent Axalimogene Filolisbac
Tuesday, 6 Oct 2015 04:01pm EDT 

Advaxis:Says that last Thursday the company received verbal notice from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for axalimogene filolisbac (formerly ADXS-HPV) has been placed on clinical hold, affecting four clinical trials.Says Ongoing clinical trials with Advaxis's other product candidates, ADXS-PSA and ADXS-HER2, are not affected by this hold and continue to actively enroll and dose patients.Advaxis is working closely with the FDA to facilitate the review and evaluation of this isolated event.Says Agency has requested additional information to support a determination that axalimogene filolisbac did not contribute to the patient's death.Says this additional information has now been provided to the FDA.Advaxis expects that this clinical hold will be resolved expeditiously and without significant interruption to our HPV clinical development program.  Full Article

More From Around the Web

BRIEF-Advaxis Inc- European Medicines Agency issued an advanced therapy medicinal product certificate

* Advaxis Inc - European Medicines Agency issued an advanced therapy medicinal product certificate for manufacturing quality and non-clinical data Source text for Eikon: Further company coverage: